KRAS mutational status of endoscopic biopsies matches resection specimens

Journal of Clinical Pathology

Volumn 65, Issue 7, 2012, Pages 604-607

  Yang, Qing Hua ^a   Schmidt, Jason ^a   Soucy, Genvieve ^b   Odze, Robert ^b   Dejesa Jamanila, Liza ^c   Arnold, Keely ^c   Kuslich, Christine ^c   Lash, Richard ^a  

^a MIRACA LIFE SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CARIS LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KRAS; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; ENDOSCOPIC BIOPSY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

ADENOCARCINOMA; BIOPSY; COLON; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTUM; SEQUENCE ANALYSIS, DNA;

EID: 84863571928     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200746     Document Type: Article

References (44)

1. McGrath JP, Capon DJ, Smith DH, et al. Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 1983;304:501-6. (Pubitemid 13026945)
2. Popescu NC, Amsbaugh SC, DiPaolo JA, et al. Chromosomal localization of three human ras genes by in situ molecular hybridization. Somat Cell Mol Genet 1985;11:149-55. (Pubitemid 15149288)
3. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005;1756:81-2.
4. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1193-7.
5. Licar A, Cerkovnik P, Ocvirk J, et al. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010;36:1137-44.
6. Herreros-Villanueva M, Rodrigo M, Claver M, et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011;38:1315-20.
7. Nash GM, Gimbel M, Cohen AM, et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 2010;17:416-24.
8. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010;17:572-8.
9. Cejas P, Lopez-Gomez M, Aguaya C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009;4:e8199.
10. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
11. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
12. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010;28:1181-9.
13. Boccia RV, Cosgriff TM, Headley DL, et al. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2010;9:102-7.
14. Addeo R, Caraglia M, Cerbone D, et al. Panituumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2010;10:499-505.
15. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010;70:1059-78.
16. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010;32:437-53.
17. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010;16:2921-6.
18. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
19. Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am J Health Syst Pharm 2009;66:2105-12.
20. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnosistic analysis of metatastic colorectal cancer. Pathol Res Pract 2009;205:858-62.
21. Yen LC, Uen YH, Wu DC, et al. Activating KRAS mutations and over expression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010;251:254-60.
22. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010;29:3033-43.
23. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, et al. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monocolonal antibodies in metastatic colorectal cancer. Target Oncol 2010;5:19-28.
24. Fakih MM. KRAS mutation screening in colorectal cancer: from paper to practice. Clin Colorectal Cancer 2010;9:22-30.
25. Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep 2010;12:160-7.
26. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol 2010;5:23.
27. French D, Smith A, Powers MP, et al. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. Clin Chim Acta 2011;412:1678-81.
28. Su YH, Wang M, Brenner DE, et al. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci 2008;1137:197-206.
29. Su YH, Wang M, Aiamkitsumrit B, et al. Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark 2005;1:177-82.
30. Troncone G, Malapelle U, Cozzolino I, et al. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010;38:869-73.
31. Wu S, Zhu Z, He J, et al. A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. Clin Chem Lab Med 2010;48:1103-6.
32. Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci U S A 1989;86:2403-7. (Pubitemid 19102517)
33. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
34. Monzon FA, Ogino S, Hammond ME, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009;133:1600-6.
35. Kobunai T, Watanabe T, Yamamoto Y, et al. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 2010;395:158-62.
36. Deschoolmeester V, Boeckx C, Baay M, et al. KRAS mutation detection and prognostic potential in sporadic colorrectal cancer using high-resolution melting analysis. Br J Cancer 2010;103:1627-36.
37. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009;27:1130-6.
38. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21. (Pubitemid 41149657)
39. Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS geneotyping in routine practice: results and pitfalls. Mod Pathol 2011;24:1090-100.
40. Macedo MP, Andrade LB, Coudry R, et al. Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Int J Colorectal Dis 2011;26:1241-8.
41. Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011;34:61-6.
42. Kosakowska EA, Stec R, Charkiewicz R, et al. Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites-case report and a literature review. Folia Histochem Cytobiol 2010;48:597-602.
43. Knijn N, Mekenkamp LJM, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumors and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020-6.
44. Ondrejka SL, Schaeffer DF, Jakubowski MA, et al. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? Am J Surg Pathol 2011;35:1327-30.